RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB2 days ago — Recordati (REC.MI) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB2 days ago — Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEBRecordati shares had jumped 5.3% by 0744 GMT, while Sanofi was up 1.3%. The deal is "very positive" as it will lead to optimised production and an increase in revenues for the Italian firm, a ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB2 days ago — Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion.. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB3 days ago — Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB2 days ago — Oct 4, 2024 6:47am. By Andrea Figueras. Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB2 days ago — Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal …
Recordati shares rise as investors reportedly circle CVC stake
WEBJun 18, 2024 — Shares in Italian drugmaker Recordati rose almost 3% on Tuesday, boosted by a report that investment funds KKR and TPG had expressed preliminary interest in buying a stake in the company.
Italy's Recordati hikes 2024 guidance after core profit rises 11.5%
WEBJul 30, 2024 — Italian drug maker Recordati raised its guidance for 2024 on Tuesday buoyed by positive momentum in its mainline Specialty and Primary Care and Rare Disease segments and an 11.5% rise in...
CVC Explores Options for €11 Billion Drugmaker Recordati - Bloomberg.com
WEBApr 23, 2024 — CVC Capital Partners is exploring options for its controlling stake in Italian drugmaker Recordati SpA, according to people familiar with the matter.